The stock of Medifast Inc (NYSE: MED) has decreased by -22.70 when compared to last closing price of 35.51. Despite this, the company has experienced a -17.87% fall in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-30 that Medifast (NYSE: MED ) stock is falling on Tuesday after the weight loss company released its earnings report for the first quarter of 2024. The bad news for MED stock comes from its adjusted earnings per share of 66 cents.
Is It Worth Investing in Medifast Inc (NYSE: MED) Right Now?
Medifast Inc (NYSE: MED) has a higher price-to-earnings ratio of 3.01x compared to its average ratio, The 36-month beta value for MED is at 1.15. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MED is 10.60M, and currently, shorts hold a 28.20% of that float. The average trading volume for MED on April 30, 2024 was 391.96K shares.
MED’s Market Performance
MED’s stock has seen a -17.87% decrease for the week, with a -26.82% drop in the past month and a -51.74% fall in the past quarter. The volatility ratio for the week is 3.95%, and the volatility levels for the past 30 days are at 4.04% for Medifast Inc The simple moving average for the last 20 days is -16.97% for MED stock, with a simple moving average of -57.40% for the last 200 days.
Analysts’ Opinion of MED
Many brokerage firms have already submitted their reports for MED stocks, with Stephens repeating the rating for MED by listing it as a “Equal-Weight.” The predicted price for MED in the upcoming period, according to Stephens is $82 based on the research report published on October 13, 2023 of the previous year 2023.
DA Davidson, on the other hand, stated in their research note that they expect to see MED reach a price target of $106, previously predicting the price at $278. The rating they have provided for MED stocks is “Neutral” according to the report published on November 04th, 2022.
Jefferies gave a rating of “Hold” to MED, setting the target price at $150 in the report published on August 04th of the previous year.
MED Trading at -24.72% from the 50-Day Moving Average
After a stumble in the market that brought MED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.94% of loss for the given period.
Volatility was left at 4.04%, however, over the last 30 days, the volatility rate increased by 3.95%, as shares sank -23.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.95% lower at present.
During the last 5 trading sessions, MED fell by -19.15%, which changed the moving average for the period of 200-days by -70.44% in comparison to the 20-day moving average, which settled at $32.65. In addition, Medifast Inc saw -59.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MED starting from SCHLACKMAN SCOTT, who sale 4,053 shares at the price of $39.44 back on Mar 08 ’24. After this action, SCHLACKMAN SCOTT now owns 7,785 shares of Medifast Inc, valued at $159,866 using the latest closing price.
BROWN JEFFREY J, the Director of Medifast Inc, purchase 58 shares at $68.89 during a trade that took place back on Nov 07 ’23, which means that BROWN JEFFREY J is holding 5,784 shares at $4,020 based on the most recent closing price.
Stock Fundamentals for MED
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.73 for the gross margin
The net margin for Medifast Inc stands at 0.08. The total capital return value is set at 0.36. Equity return is now at value 55.77, with 30.17 for asset returns.
Based on Medifast Inc (MED), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 4.42. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 29.74.
Currently, EBITDA for the company is 139.51 million with net debt to EBITDA at -0.85. When we switch over and look at the enterprise to sales, we see a ratio of 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.43.
Conclusion
In conclusion, Medifast Inc (MED) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
